Diagnosis accuracy of serum glypican-3 level in patients with hepatocellular carcinoma: a systematic review with meta-analysis
Authors:
- 2 August 2018
- journal article
- review article
- Published by SAGE Publications in The International Journal of Biological Markers
- Vol. 33 (4) , 353-363
Abstract
Background: Previous studies have evaluated the diagnostic value of serum glypican-3 in patients with hepatocellular carcinoma. However, the results remain inconsistent and even controversial. Thus, the aim of the present meta-analysis was to clarify the diagnostic accuracy of serum glypican-3 for hepatocellular carcinoma. Methods: A meta-analysis including 22 studies was performed with 2325 cases and 2280 controls. Relevant studies were searched in the EMBASE, PubMed, and Web of Science databases, covering relevant papers published until November 1, 2017. The quality of the studies was assessed by revised QUADAS tools. Sensitivity, specificity, and other measures were pooled and determined to evaluate the accuracy of serum glypican-3 in the diagnosis of hepatocellular carcinoma by random-effects models. Summary receiver operating characteristic curve (sROC) analysis was performed to summarize the overall test performance. Results: The results showed that the pooled overall diagnostic sensitivity, specificity, and 95% confidence interval (CI) for serum glypican-3 in the diagnosis of hepatocellular carcinoma were 68% (56-79%) and 92% (82-96.0%), respectively. Besides, the summary diagnostic odds ratio and 95% CI for glypican-3 were 23.53 (8.57-64.63). In addition, the area under sROC and 95% CI was 0.87 (0.84-0.90). The major design deficiencies of included studies were differential verification bias, and a lack of clear exclusion and inclusion criteria. Conclusions: The results of this meta-analysis suggested that serum glypican-3 was acceptable as a moderate diagnostic marker in the diagnosis of hepatocellular carcinoma compared with healthy individuals, which could elevate the sensitivity and specificity of diagnosis. Furthermore, more well-designed studies with large sample sizes are needed to show the effectiveness of glypican-3 in the differential diagnosis of hepatocellular carcinoma.Keywords
This publication has 39 references indexed in Scilit:
- QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy StudiesAnnals of Internal Medicine, 2011
- Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinomaWorld Journal of Gastroenterology, 2010
- Diagnostic role of serum glypican‐3 in differentiating hepatocellular carcinoma from non‐malignant chronic liver disease and other liver cancersJournal of Gastroenterology and Hepatology, 2009
- AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver diseaseBMC Cancer, 2008
- Short- and Long-Term Outcomes after Hepatic Resection for Hepatocellular Carcinoma with Concomitant Esophageal Varices in Patients with CirrhosisAnnals of Surgical Oncology, 2008
- Gene Expression Profiling Reveals Potential Biomarkers of Human Hepatocellular CarcinomaClinical Cancer Research, 2007
- New aspects of diagnosis and therapy of hepatocellular carcinomaOncogene, 2006
- The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessedJournal of Clinical Epidemiology, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003
- Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disordersGut, 2001